Researchers have successfully used monoclonal antibodies to protect animal models from Candida infections for the first time, demonstrating their potential for treating this fungal disease.
Browsing: Basic > Pre-clinical Trials
Researchers from the University of Zurich have discovered that thanatin, a compound produced naturally by the spined soldier bug, could target Gram-negative bacteria by preventing formation of the bacteria’s outer membrane – an unprecedented mechanism.
Small molecules that block bacterial toxin formation have shown promise against Gram-positive bacteria in mouse models.
Experimental HIV-1 vaccine regimen is safe and elicits a robust immune response according to results of a Phase I/IIa clinical trial.
Recent technological advancements have allowed organoids to become a viable research tool for a wide range of development and disease models. Here, we look at some of the research that’s been done in infectious diseases and delve into what the future of organoids might look like.
A high-fiber diet can boost the immune response and increase survival in mice infected with influenza virus, according to new research.
Two genetically-modified broadly-neutralizing antibodies have been demonstrated to elicit long-term protection against an HIV-like virus in rhesus macaques, with a Phase I clinical trial now underway.
In this interview, we speak to Dr. Bryan Kraft, an Assistant Professor of Medicine at Duke University, about his research into carbon monoxide as a potential therapy to treat ARDS and the clinical trial for this therapy that is currently underway.
Learn more about the top news stories of the week in our round-up, including new guidance for drug-resistant infections and a Phase I trials for a MERS treatment.
Researchers have developed a drug delivery system that could allow antiretroviral drugs for HIV to be administered only once a week, potentially making it easier for patients to adhere to drug regimens.